First-line treatment of Minimal change disease: achieving complete remission of nephrotic syndrome

Minimal change disease (MCD) is a primary cause of nephrotic syndrome. First-line management follows structured evidence-based recommendations directed at inducing complete remission.

Treatment approach

Initial therapy is based on a high-dose oral glucocorticoid course. The complete regimen — including dosing strategy, duration, and taper schedule — is set out in the full structured protocol.

Clinical goals

The primary aim is complete remission of nephrotic syndrome. Approximately 50% of patients respond by 4 weeks; an additional 10–25% may achieve remission after a longer treatment course.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1038/kisup.2012.18

We recommend high-dose oral glucocorticoids for initial treatment of MCD (1C).
MCD is typically responsive to glucocorticoids, with over 80% of patients achieving remission.
Only 50% of patients will respond after 4 weeks of glucocorticoid, but an additional 10%–25% may respond after a total of 16 weeks of treatment.

View source ↗